The key reported efficacy results were striking:

• Progression‑free survival (PFS): 11.3 months in the early group vs. 5.7 months in the late group; hazard ratio 0.40 (95% CI 0.29–0.55; p < 0.001) .
• Overall survival (OS): the study reported longer OS in the early‑treatment group than in the late‑treatment group .

The paper also claimed that early time‑of‑day immunochemotherapy was linked to enhanced antitumor immune characteristics, including increased activated CD8+ T cells and a more favorable ratio of activated to exhausted T cells, with no increase in treatment‑related adverse events .

These results were widely covered because the reported PFS difference suggested roughly a doubling of median progression‑free survival for patients treated before 3 PM .

Why the paper was retracted

Nature Medicine retracted the paper on June 24 2026 after a four‑month investigation . The journal cited multiple specific problems:

• Protocol‑lock violations: Records that were supposed to be locked before the study started were reportedly changed midway through the trial .
• Language discrepancies: There were discrepancies between the Chinese version of the study’s plan and the translated version .
• Unusually clean safety data: Every patient remained treated and tracked in the study’s first year, and no one dropped out because of side effects — a pattern that oncologists described as highly unusual in an oncology study .
• Unusual data patterns: Unusual patterns were found in the reported patient data .

The journal stated: "Due to the amount and nature of the problems identified, the editors no longer have confidence in the integrity of the results" . The Boston Globe covered the retraction under the headline that some observers had viewed the results as "too good to be true" .

What the broader evidence now says about time‑of‑day scheduling

The biological rationale for circadian timing is plausible — immune cells follow a circadian rhythm, and preclinical work has shown that the tolerability and efficacy of chemotherapeutic and immunotherapeutic agents can vary by time of day . However, the clinical evidence is far from settled.

Evidence suggesting timing may matter (largely observational):

• A bicentric, bicontinental retrospective study of patients receiving first‑line immuno‑chemotherapy for advanced NSCLC found that those treated before 11:30 AM had significantly better overall survival (median 33.0 vs. 19.5 months; adjusted HR 0.47) .
• A meta‑analysis of time‑of‑day immunotherapy studies that included 1 randomized clinical trial in NSCLC, 1 prospective cohort study, and 27 retrospective cohort studies across multiple cancer types reported that earlier ICI administration was associated with improved OS (HR 0.60; 95% CI 0.51–0.70) and PFS (HR 0.66; 95% CI 0.55–0.79) .

Evidence suggesting timing may not matter (large‑scale meta‑analysis):

• The ETOP‑Roche i‑TIMES study, a patient‑level meta‑analysis of data from 8 randomized trials in lung cancer presented at the European Lung Cancer Congress 2026, found that late‑day administration of immunotherapy was non‑inferior to early‑day administration for overall survival. Median OS was 16.0 months in patients who received their first 2 cycles after 12:00 vs. 17.3 months in those treated before 12:00, with an HR of 1.039 (95% CI 0.925–1.168) . The study authors concluded that timing within the day is unlikely to be a key determinant of efficacy .

Reasons for continuing caution:

• The strongest prospective randomized trial that appeared to support early‑day immunotherapy (LungTIME‑C01) has been retracted, so its reported PFS and OS results should not be relied on as definitive evidence .
• Most of the positive clinical evidence is retrospective or observational, which is subject to confounding and selection bias .
• Ongoing real‑world evaluations, including an NCI‑listed study evaluating real‑world PFS and OS in NSCLC patients receiving first‑line ICI therapy early vs. later in the day, may help clarify the question .

Bottom line

The safest conclusion: circadian timing of immunotherapy is a biologically plausible but clinically unproven hypothesis. The LungTIME‑C01 retraction removes the strongest prospective evidence for it, leaving the field reliant mainly on observational and heterogeneous evidence while awaiting more definitive prospective validation .

The key reported efficacy results were striking:

• Progression‑free survival (PFS): 11.3 months in the early group vs. 5.7 months in the late group; hazard ratio 0.40 (95% CI 0.29–0.55; p < 0.001) .
• Overall survival (OS): the study reported longer OS in the early‑treatment group than in the late‑treatment group .

The paper also claimed that early time‑of‑day immunochemotherapy was linked to enhanced antitumor immune characteristics, including increased activated CD8+ T cells and a more favorable ratio of activated to exhausted T cells, with no increase in treatment‑related adverse events .

These results were widely covered because the reported PFS difference suggested roughly a doubling of median progression‑free survival for patients treated before 3 PM .

Why the paper was retracted

Nature Medicine retracted the paper on June 24 2026 after a four‑month investigation . The journal cited multiple specific problems:

• Protocol‑lock violations: Records that were supposed to be locked before the study started were reportedly changed midway through the trial .
• Language discrepancies: There were discrepancies between the Chinese version of the study’s plan and the translated version .
• Unusually clean safety data: Every patient remained treated and tracked in the study’s first year, and no one dropped out because of side effects — a pattern that oncologists described as highly unusual in an oncology study .
• Unusual data patterns: Unusual patterns were found in the reported patient data .

The journal stated: "Due to the amount and nature of the problems identified, the editors no longer have confidence in the integrity of the results" . The Boston Globe covered the retraction under the headline that some observers had viewed the results as "too good to be true" .

What the broader evidence now says about time‑of‑day scheduling

The biological rationale for circadian timing is plausible — immune cells follow a circadian rhythm, and preclinical work has shown that the tolerability and efficacy of chemotherapeutic and immunotherapeutic agents can vary by time of day . However, the clinical evidence is far from settled.

Evidence suggesting timing may matter (largely observational):

• A bicentric, bicontinental retrospective study of patients receiving first‑line immuno‑chemotherapy for advanced NSCLC found that those treated before 11:30 AM had significantly better overall survival (median 33.0 vs. 19.5 months; adjusted HR 0.47) .
• A meta‑analysis of time‑of‑day immunotherapy studies that included 1 randomized clinical trial in NSCLC, 1 prospective cohort study, and 27 retrospective cohort studies across multiple cancer types reported that earlier ICI administration was associated with improved OS (HR 0.60; 95% CI 0.51–0.70) and PFS (HR 0.66; 95% CI 0.55–0.79) .

Evidence suggesting timing may not matter (large‑scale meta‑analysis):

• The ETOP‑Roche i‑TIMES study, a patient‑level meta‑analysis of data from 8 randomized trials in lung cancer presented at the European Lung Cancer Congress 2026, found that late‑day administration of immunotherapy was non‑inferior to early‑day administration for overall survival. Median OS was 16.0 months in patients who received their first 2 cycles after 12:00 vs. 17.3 months in those treated before 12:00, with an HR of 1.039 (95% CI 0.925–1.168) . The study authors concluded that timing within the day is unlikely to be a key determinant of efficacy .

Reasons for continuing caution:

• The strongest prospective randomized trial that appeared to support early‑day immunotherapy (LungTIME‑C01) has been retracted, so its reported PFS and OS results should not be relied on as definitive evidence .
• Most of the positive clinical evidence is retrospective or observational, which is subject to confounding and selection bias .
• Ongoing real‑world evaluations, including an NCI‑listed study evaluating real‑world PFS and OS in NSCLC patients receiving first‑line ICI therapy early vs. later in the day, may help clarify the question .

Bottom line

The safest conclusion: circadian timing of immunotherapy is a biologically plausible but clinically unproven hypothesis. The LungTIME‑C01 retraction removes the strongest prospective evidence for it, leaving the field reliant mainly on observational and heterogeneous evidence while awaiting more definitive prospective validation .